Abstract
Noninvasive mechanical ventilation (NIV) is an effective treatment in acute hypercapnic respiratory failure associated with exacerbated chronic obstructive pulmonary disease and obesity hypoventilation syndrome, among other respiratory diseases. There is less scientific evidence on its application in situations of acute hypoxemic respiratory failure other than acute lung edema. There have been few randomized controlled trials on its efficacy versus standard oxygen therapy or conventional mechanical ventilation in the treatment of severe community-acquired pneumonia, and the results have been contradictory. Its application in selected immunosuppressed patients and patients with acute hypoxemic respiratory failure or chronic obstructive pulmonary disease-associated community-acquired pneumonia may reduce the orotracheal intubation rate, hospital stay, and mechanical ventilation-associated morbidity and mortality. A therapeutic trial with NIV may be appropriate in these situations, but only when the treatment can be continuously monitored and is controlled by specifically-trained professionals.
Keywords: Noninvasive ventilation, pneumonia, randomized controlled trials, acute hypoxemic respiratory failure, acute hypercapnic respiratory failure, COPD
Current Respiratory Medicine Reviews
Title: Noninvasive Mechanical Ventilation in the Treatment of Community-Acquired Pneumonia
Volume: 6 Issue: 3
Author(s): Angel Ortega-Gonzalez, Maria Jesus Cobos-Ceballos, Jose Carlos Serrano-Rebollo, Teresa Vargas-Hidalgo, Maximo Gomez-Fernandez, Jose Javier Garcia-Lopez and Jose Celdran-Gil
Affiliation:
Keywords: Noninvasive ventilation, pneumonia, randomized controlled trials, acute hypoxemic respiratory failure, acute hypercapnic respiratory failure, COPD
Abstract: Noninvasive mechanical ventilation (NIV) is an effective treatment in acute hypercapnic respiratory failure associated with exacerbated chronic obstructive pulmonary disease and obesity hypoventilation syndrome, among other respiratory diseases. There is less scientific evidence on its application in situations of acute hypoxemic respiratory failure other than acute lung edema. There have been few randomized controlled trials on its efficacy versus standard oxygen therapy or conventional mechanical ventilation in the treatment of severe community-acquired pneumonia, and the results have been contradictory. Its application in selected immunosuppressed patients and patients with acute hypoxemic respiratory failure or chronic obstructive pulmonary disease-associated community-acquired pneumonia may reduce the orotracheal intubation rate, hospital stay, and mechanical ventilation-associated morbidity and mortality. A therapeutic trial with NIV may be appropriate in these situations, but only when the treatment can be continuously monitored and is controlled by specifically-trained professionals.
Export Options
About this article
Cite this article as:
Ortega-Gonzalez Angel, Jesus Cobos-Ceballos Maria, Carlos Serrano-Rebollo Jose, Vargas-Hidalgo Teresa, Gomez-Fernandez Maximo, Javier Garcia-Lopez Jose and Celdran-Gil Jose, Noninvasive Mechanical Ventilation in the Treatment of Community-Acquired Pneumonia, Current Respiratory Medicine Reviews 2010; 6 (3) . https://dx.doi.org/10.2174/157339810791526210
DOI https://dx.doi.org/10.2174/157339810791526210 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Reducing Perioperative Myocardial Infarction with Anesthetic Drugs and Techniques
Current Drug Targets Receptor Fragments: Intracellular Signaling and Novel Therapeutic Targets
Current Hypertension Reviews Aptamers: Molecular Tools for Medical Diagnosis
Current Topics in Medicinal Chemistry Oral Antidiabetic Agents: Anti-Atherosclerotic Properties Beyond Glucose Lowering?
Current Pharmaceutical Design Effectiveness and Safety of Digoxin on Chronic Heart Failure
Current Pharmaceutical Analysis Regulatory Role of Brg1 and Brm in the Vasculature: From Organogenesis to Stress-Induced Cardiovascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Anti-HIV Drug Development: Structural Features and Limitations of Present Day Drugs and Future Challenges in the Successful HIV/AIDS Treatment
Current Pharmaceutical Design Hypoglycemia and Cardiac Arrhythmia; Mechanisms, Evidence Base a nd Current Recommendations
Current Diabetes Reviews Peptido-Targeting of the Mitochondrial Transition Pore Complex for Therapeutic Apoptosis Induction
Current Pharmaceutical Design Present Insights on Cardiomyopathy in Diabetic Patients
Current Diabetes Reviews Candidate Circulating Biomarkers for the Cardiovascular Disease Continuum
Current Pharmaceutical Design Bioactive Milk Lipids
Current Nutrition & Food Science Use of Medications for the Treatment of Alcohol Dependence: A Retrospective Study Conducted in 2011-2012
Current Drug Research Reviews The Emerging Role of Vascular Endothelial Growth Factor (VEGF) in Vascular Homeostasis: Lessons from Recent Trials with Anti-VEGF Drugs
Current Vascular Pharmacology Skeletal Muscle Derived Stem Cells for Myocardial Repair
Recent Patents on Cardiovascular Drug Discovery Pharmacokinetics of Topical Ocular Drug Delivery: Potential Uses for the Treatment of Diseases of the Posterior Segment and Beyond
Current Drug Metabolism The Diagnostic and Prognostic Value of Brain Natriuretic Peptide and Aminoterminal (nt)-pro Brain Natriuretic Peptide
Current Pharmaceutical Design The Role of AGEs in Cardiovascular Disease
Current Pharmaceutical Design Recent Advances in Gene Therapy of Endometriosis
Recent Patents on DNA & Gene Sequences ALDH2---The Genetic Polymorphism and Enzymatic Activity Regulation: Their Epidemiologic and Clinical Implications
Current Drug Targets